ArticleCureus2025
Characteristics and Outcomes of Immunocompromised Patients With COVID-19 Infection Admitted to an Intensive Care Unit: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The clinical application of metagenomic next-generation sequencing for invasive pulmonary aspergillosis in neutropenic patients: a multicenter retrospective study in the ICU.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Several studies have reported that the course of illness is different in immunocompromised and non-immunocompromised patients with COVID-19 infection. The impact of COVID-19 on immunocompromised patients is not clear due to conflicting evidence from different observational studies. Aim This study aimed to compare the characteristics and outcomes of immunocompromised and non-immunocompromised patients with COVID-19 infection admitted to an intensive care unit and to evaluate whether the immunocompromised status is associated with increased mortality. Methods We conducted this retrospective cohort study using an electronic database in St. George Hospital, a tertiary ICU in Sydney. We included all adult patients (age >16 years) admitted to the ICU with COVID-19 infection over a 33-month period (March 1, 2020, to November 30, 2022). We collected the data on demographics, comorbidities, clinical characteristics, interventions, and outcomes for all patients. We used logistic regression and multivariate adaptive regression splines (MARS) to determine the predictors of mortality. We used propensity score analyses to check whether immunocompromised patients had higher hospital mortality compared to non-immunocompromised patients. Results A total of 258 patients (mean age 61 ± 16 years, males 65%, mean APACHE II score 14 ± 5, unvaccinated 58%, and immunocompromised 17%) were studied. The immunocompromised patients were older, had higher APACHE II and III scores, and had a higher vaccination rate. The hospital mortality was higher in immunocompromised patients (39.5% vs. 14.4%, p < 0.001). On multivariate logistic regression, age (OR 1.05, 95% CI 1.01-1.1, p = 0.02), APACHE III (OR 1.05, 95% CI 1.02-1.09, p < 0.001), vasopressor use (OR 6.7, 95% CI 2.6-17.2, p < 0.001), and single-dose vaccination (OR 3.76, 95% CI 1.19-11.9, p = 0.02) were independent predictors of mortality. APACHE III (score > 70) was the only variable of importance using the MARS model. The "covariate balancing propensity score" analysis did not reveal increased mortality in immunocompromised patients (OR 2.02, 95% CI 0.78-5.23, p = 0.14). Conclusion In this small, single-center study, an immunocompromised state was not an independent predictor of hospital mortality. The prediction models for risk of death indicated a trend towards increased mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.